方法：回顾性病例系列研究。分析30例30眼雷珠单抗玻璃体腔注射0.5mg每月1次，连续3次治疗湿性老年黄斑变性的病例和28例30眼康柏西普玻璃体腔注射0.5mg每月1次，连续3次治疗湿性老年黄斑变性的病例，比较两组分别在玻璃体腔注药1mo后的最佳矫正视力及OCT变化情况。

结果：连续3次玻璃体腔注药，每次治疗后1mo与治疗前相比，A 组 BCVA 平均值提高，CMT平均值降低，差异具有统计学意义(P<0.05)； B组BCVA 平均值提高， CMT平均值亦降低，差异具有统计学意义(P<0.05)，两组间比较 BCVA 变化、CMT变化差异不具有统计学意义(P>0.05)。

结论：雷珠单抗和康柏西普治疗均能有效控制湿性AMD患者病情发展并改善视力，治疗3mo内两种药物疗效的比较无统计学意义。

METHODS: This was a retrospective case series study. Thirty patients(30 eyes)with wAMD were enrolled to receive intravitreal injections of ranibizumab(0.5mg)on 3 consecutive monthly schedule and 28 patients(30 eyes)with wAMD were enrolled to receive intravitreal injections of conbercept(0.5mg)on 3 consecutive monthly schedule. Best corrected visual acuity(BCVA), optic coherence tomography(OCT)measurement were compared at 1mo after injections.

RESULTS: One month after every injection, the BCVA increased while the central macular thickness(CMT)decreased compared with those before treatment in group A and B(P<0.05). BCVA and CMT changes between two groups were no statistically different(P>0.05).

CONCLUSION:Ranibizumab and conbercept therapy can control the prognosis of wAMD and improve the vision effectively. There is no statistical difference on the curative effect between two drugs for 3mo.